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ABSTRACT
Background. Neratinib has efﬁcacy in central nervous system
(CNS) metastases from HER2-positive metastatic breast cancer
(MBC). We report outcomes among patients with CNS metastases at baseline from the phase III NALA trial of neratinib plus
capecitabine (N + C) versus lapatinib plus capecitabine (L + C).
Materials and Methods. NALA was a randomized, activecontrolled trial in patients who received two or more previous
HER2-directed regimens for HER2-positive MBC. Patients with
asymptomatic/stable brain metastases (treated or untreated)
were eligible. Patients were assigned to N + C (neratinib 240
mg per day, capecitabine 750 mg/m2 twice daily) or L + C (lapatinib 1,250 mg per day, capecitabine 1,000 mg/m2 twice daily)
orally. Independently adjudicated progression-free survival
(PFS), overall survival (OS), and CNS endpoints were considered.
Results. Of 621 patients enrolled, 101 (16.3%) had known
CNS metastases at baseline (N + C, n = 51; L + C, n = 50);

81 had received prior CNS-directed radiotherapy and/or
surgery. In the CNS subgroup, mean PFS through 24 months
was 7.8 months with N + C versus 5.5 months with L + C
(hazard ratio [HR], 0.66; 95% conﬁdence interval [CI], 0.41–
1.05), and mean OS through 48 months was 16.4 versus
15.4 months (HR, 0.90; 95% CI, 0.59–1.38). At 12 months,
cumulative incidence of interventions for CNS disease was
25.5% for N + C versus 36.0% for L + C, and cumulative
incidence of progressive CNS disease was 26.2% versus
41.6%, respectively. In patients with target CNS lesions at
baseline (n = 32), conﬁrmed intracranial objective response
rates were 26.3% and 15.4%, respectively. No new safety
signals were observed.
Conclusion. These analyses suggest improved PFS and CNS outcomes with N + C versus L + C in patients with CNS metastases
from HER2-positive MBC. The Oncologist 2021;26:e1327–e1338

Implications for Practice: In a subgroup of patients with central nervous system (CNS) metastases from HER2-positive
breast cancer after two or more previous HER2-directed regimens, the combination of neratinib plus capecitabine was associated with improved progression-free survival and CNS outcomes compared with lapatinib plus capecitabine. These ﬁndings
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build on previous phase II and III studies describing efﬁcacy of neratinib in the prevention and treatment of CNS metastases,
and support a role for neratinib as a systemic treatment option in the management of patients with HER2-positive brain
metastases following antibody-based HER2-directed therapies.

INTRODUCTION

MATERIALS AND METHODS
Study Design and Patients
NALA was an international, randomized, multicenter, openlabel, active-controlled, parallel-design study conducted at
203 sites in 28 countries in Europe, North and South
America,
Asia,
and
Australia
(clinicaltrials.gov:
NCT01808573), the details of which have been described
previously [16]. Randomization was stratiﬁed by hormone
receptor status (hormone receptor-positive or hormone
receptor-negative), number of previous HER2-directed therapies for metastatic disease (2 or ≥ 3), geographic region
(North America or Europe [including Israel] or rest of
world), and location of disease (visceral or nonvisceral).
Within the NALA study population (n = 621), there
were 101 patients (16.3%) with CNS metastases at baseline,
deﬁned as patients with treated or untreated disease in the
“brain” as assessed by the investigator at enrollment. Baseline brain imaging (magnetic resonance imaging [MRI], etc).
was not mandatory for any patient, regardless of history of
CNS involvement, but performed if clinically indicated per
investigator assessment. According to the study inclusion
criteria, asymptomatic patients with metastatic brain disease, including leptomeningeal disease (LMD), who were on
stable doses of corticosteroids (without any dose limit) for
the treatment of brain metastases for at least 14 days prior
to randomization were eligible. Previous surgery and radiation therapy was permitted if completed within 28 days
and 14 days, respectively, before starting study treatment.
Patients with symptomatic or unstable brain metastases
were not allowed. The protocol was approved by national/
institutional ethics committees at participating sites, and
the study was conducted in accordance with the Declaration of Helsinki. Patients provided written informed consent
prior to enrollment.

Treatment
Patients received neratinib 240 mg once daily plus
capecitabine 750 mg/m2 twice daily or lapatinib 1,250 mg
once daily plus capecitabine 1,000 mg/m2 twice daily orally.
Neratinib and lapatinib were given continuously, whereas
capecitabine was administered on days 1–14 of a 21-day
cycle. Treatment was discontinued on disease progression
(even for isolated brain metastases), initiation of alternative
anticancer therapy, or other speciﬁed criteria. Dose modiﬁcations and/or discontinuation speciﬁed by protocol were
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HER2-directed agents have altered the natural history of
HER2-positive breast cancer, achieving marked improvements in the control of systemic disease but with an accompanying increase in the occurrence or progression of central
nervous system (CNS) metastases [1]. In early-stage disease,
the brain is a common ﬁrst site of metastasis after
HER2-directed adjuvant therapy (35%–55% of distant
recurrences) [2–4], whereas in the metastatic setting, 30%–
55% of patients develop CNS metastases [5], highlighting
the need for multiple lines of safe and effective CNSdirected treatments.
Management of CNS metastases primarily involves local
therapy including stereotactic radiosurgery, whole-brain
radiotherapy, and surgery. Historically, systemic treatment
options were limited because patients with CNS metastasis
were often excluded from clinical trials and because there
was a reluctance to use HER2-directed monoclonal antibodies based on a presumed inability to cross the bloodbrain barrier [6]. However, accumulating clinical evidence
suggests that HER2-directed therapies can ameliorate brain
metastases [7–9], and, for the ﬁrst time, a systemic treatment, the reversible HER2-speciﬁc tyrosine kinase inhibitor
(TKI) tucatinib, has been approved for use in brain metastases from HER2-positive breast cancer in combination with
trastuzumab and capecitabine [10].
Neratinib (Nerlynx; Puma Biotechnology Inc, Los
Angeles, CA), an irreversible small-molecule pan-HER TKI,
has been approved by the US Food and Drug Administration
for use in combination with capecitabine in patients with
advanced/metastatic HER2-positive breast cancer who have
received two or more prior anti-HER2–based regimens in
the metastatic setting, as well as for the extended adjuvant
treatment of patients with early-stage HER2-positive breast
cancer following trastuzumab-based therapy [11]. Of note,
neratinib has demonstrated efﬁcacy in both the prevention
[12, 13] and treatment [14–16] of CNS metastases from
HER2-positive breast cancer. In the recent phase III NALA
trial, neratinib plus capecitabine (N + C) signiﬁcantly
improved progression-free survival (PFS) compared with
lapatinib plus capecitabine (L + C) in patients with HER2positive metastatic breast cancer (MBC) who had received
at least two previous HER2-directed regimens for metastatic
disease (hazard ratio [HR], 0.76; 95% conﬁdence interval
[CI], 0.63–0.93; p = .0059) [16]. There was also a numerical
difference favoring N + C for overall survival (OS), but statistical signiﬁcance was not reached (HR, 0.88; 95% CI,
0.72–1.07; p = .2086). Fewer interventions for CNS disease
were required with N + C versus L + C (p = .043) [16].
Within the NALA study population, a cohort of
101 patients had CNS metastases at baseline. We report
efﬁcacy, safety, and health-related quality-of-life (HRQoL)
outcomes in this patient subgroup, with a particular focus

on CNS-speciﬁc endpoints. Lapatinib, a reversible dual TKI,
plus capecitabine was selected as the active comparator
regimen for NALA as it is a recognized treatment option for
patients with previously treated HER2-positive MBC [17]
and has well-documented efﬁcacy in the CNS [18–20].
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performed in cases of treatment-emergent adverse events
(TEAEs). Antidiarrheal prophylaxis with loperamide as
described previously [16] was required per protocol for all
patients randomized to N + C for the duration of cycle 1.
Hormonal therapy during the active study treatment phase
was not permitted.

Tumor assessments were performed using MRI or computerized tomography at baseline and then every 6 weeks from
ﬁrst dose of study treatment. CNS tumor assessments were
not a prerequisite for enrollment and were followed
according to the same schedule of assessments as extracranial tumors; for all patients, ad hoc CNS imaging was performed if clinically indicated per investigator assessment.
Patients who discontinued study therapy were contacted
via telephone every 12 weeks for survival status and to collect data concerning interventions for CNS disease. TEAEs
were monitored until 28 days after the last dose of study
drug and graded according to National Cancer Institute
Common Terminology Criteria Adverse Events, v4.0. HRQoL
was assessed using the European Organisation for Research
and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire (QLQ-C30; version 3) and breast cancer-speciﬁc module (QLQ-BR23) at screening, every 6 weeks during
treatment, and at treatment discontinuation.

Endpoints
Independently adjudicated PFS and OS were evaluated in
the CNS population. CNS-speciﬁc endpoints were time to
intervention for metastatic CNS disease, deﬁned as time
from randomization to start of therapy for CNS disease,
with interventions for CNS disease including anticancer
medication, cancer-related radiation therapy, cancer-related
surgery/procedure, or concomitant medication/therapy as
collected on the CNS case report form; time to progressive
CNS lesions, deﬁned as time from randomization until

Statistical Analysis
All analyses in this CNS subgroup are descriptive, and
p values presented are without multiplicity adjustments.
Time-to-event endpoints were analyzed using the KaplanMeier method, and treatment groups were compared using
a log-rank test and Cox proportional hazards model to estimate HR and 95% CI. The restricted mean survival time
method was used as a prespeciﬁed sensitivity analysis for
PFS (24-month time point) and OS (48-month time point) in
the patient population with CNS metastases at baseline and
was performed in the intention-to-treat population [16].
Cumulative incidence of interventions for CNS was analyzed
by competing risks analysis and tested via Gray’s method
[22], where competing events were deaths without intervention for CNS disease. CNS progression was analyzed by
competing risks analysis, where competing events were
progression at other sites and deaths prior to CNS progression. Conﬁrmed intracranial ORR with exact 95% CI was provided. The analysis cutoff date was September 28, 2018.
SAS statistical software, version 9.1 or later, was used.

RESULTS
Patients
Between May 2013 and July 2017, 621 patients were randomized to study treatment. Overall, 101 patients (16.3%)

Figure 1. CONSORT ﬂowchart.

www.TheOncologist.com

© 2021 The Authors.
The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.

Downloaded from https://academic.oup.com/oncolo/article/26/8/e1327/6511607 by Washington University in St. Louis user on 24 September 2022

Assessments

newly diagnosed or progressive CNS lesions (scans read
centrally); CNS-PFS, deﬁned as time from randomization to
disease progression in the brain or death from any cause,
whichever occurred ﬁrst (scans read centrally); and intracranial objective response rate (ORR), deﬁned as conﬁrmed
complete or partial responses in patients with target CNS
lesions according to local investigator assessment using
RECIST v1.1 [21]. See supplemental online Table 1 for deﬁnitions of all endpoints.
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Table 1. Demographics and baseline characteristics of patients with and without CNS metastases at baseline
CNS metastases
Characteristic

N + C (n = 51)

L + C (n = 50)

Total (n = 101)

53 (25–71)

54 (26–75)

54 (25–75)

51 (100)

50 (100)

101 (100)

No CNS metastases,
total (n = 520)

Age, yr
Median (range)

55 (25–84)

Sex
517 (99.4)

Europe

18 (35.3)

14 (28.0)

32 (31.7)

212 (40.8)

North America

9 (17.6)

13 (26.0)

22 (21.8)

102 (19.6)

Rest of world

24 (47.1)

23 (46.0)

47 (46.5)

206 (39.6)

0

21 (41.2)

22 (44.0)

43 (42.6)

295 (56.7)

1

30 (58.8)

28 (56.0)

58 (57.4)

225 (43.3)

2.9 (0.9–16.2)a

3.2 (0.8–20.2)

2.9 (0.8–20.2)

3.6 (0.5–25.1)

51 (100)

50 (100)

101 (100)

430 (82.7)

ECOG performance status

Time from diagnosis to randomization, yr
Median (range)
Disease location
Visceral
Brain

b

Lung
Liver

51 (100)

50 (100)

101 (100)

0 (0)

29 (56.9)

34 (68.0)

63 (62.4)

267 (51.3)

29 (56.9)

27 (54.0)

56 (55.4)

229 (44.0)

39 (76.5)

46 (92.0)

85 (84.2)

441 (84.8)

Lymph node

27 (52.9)

29 (58.0)

56 (55.4)

289 (55.6)

Bone

28 (54.9)

34 (68.0)

62 (61.4)

256 (49.2)

Negative

28 (54.9)

22 (44.0)

50 (49.5)

204 (39.2)

Positive

23 (45.1)

28 (56.0)

51 (50.5)

316 (60.8)

2

42 (82.4)

33 (66.0)

75 (74.3)

355 (68.3)

≥3

9 (17.6)

17 (34.0)

26 (25.7)

165 (31.7)

Neoadjuvant

5 (9.8)

8 (16.0)

13 (12.9)

112 (21.5)

Adjuvant

16 (31.4)

23 (46.0)

39 (38.6)

256 (49.2)

51 (100)

50 (100)

101 (100)

519 (99.8)

No prior surgery or radiation

7 (13.7)

13 (26.0)

20 (19.8)

Prior radiation

43 (84.3)

35 (70.0)

78 (77.2)

Whole-brain radiatione

34 (66.7)

30 (60.0)

64 (63.4)

Stereotactic radiation only

Nonvisceral

Hormone receptor statusc

Prior HER2 regimens

Prior anticancer medication

Metastatic/locally advanced
Prior CNS-directed therapies

d

9 (17.6)

5 (10.0)

14 (13.9)

Prior surgery

2 (3.9)

3 (6.0)

5 (5.0)

Prior surgery plus radiation

1 (2.0)

1 (2.0)

2 (2.0)

Antiepileptic agents

7 (13.7)

3 (6.0)

10 (9.9)

Corticosteroids

12 (23.5)

9 (18.0)

21 (20.8)

Dexamethasone dose equivalent, mg/dayf

12

6

18

Median (range)

2.5 (0.8–8.0)

4.0 (0.8–4.0)

3.5 (0.8–8.0)

Concomitant CNS medications at baseline

Data presented as n (%) unless otherwise stated.
a
n = 50.
b
Two patients in the N + C group and one patient in the L + C group indicated location as other, with additional explanations indicating brain.
c
Hormone receptor-positive: estrogen receptor-positive, progesterone receptor-positive, or both. Hormone receptor-negative: estrogen
receptor- and progesterone receptor-negative.
d
CNS-directed therapies were only reviewed for patients with CNS metastases (n = 101) at baseline.
e
Patients may have documented both targeted and whole-brain radiotherapy.
f
Three patients had incorrect doses or units and were not included. Corticosteroid doses were converted to dexamethasone dose equivalents
according to Parente [23].
Abbreviations: CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group; L + C, lapatinib plus capecitabine; N + C, neratinib
plus capecitabine.
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A

Figure 2. Progression-free survival by independent adjudication (A) and overall survival (B) in patients with central nervous system
metastases at baseline.
Abbreviation: CI, conﬁdence interval.

had CNS metastases at baseline (N + C, n = 51; L + C,
n = 50); 99 patients from this subgroup received study
treatment and were evaluated for safety (N + C, n = 50;
L + C, n = 49; see Fig. 1). Compared with patients without
CNS metastases (n = 520), patients with CNS metastases
were more likely to have an ECOG performance status of
1 (57.4% vs. 43.3%) and hormone receptor-negative disease
(49.5% vs. 39.2%). Accompanying visceral (mainly lung and
liver) and nonvisceral lesions (mainly bone and lymph
nodes) were common (Table 1).
Within the CNS subgroup, demographics and disease
characteristics were generally well balanced between treatment groups (Table 1), except hormone receptor-negative
disease was more common in the N + C group (54.9% vs.
L + C, 44.0%), and patients in the N + C group were less
likely to have received three or more HER2-directed therapies in the metastatic setting (17.6% vs. 34.0%). Twenty
patients (19.8%) had received no CNS-directed radiotherapy
or surgery at the time of enrollment, 78 patients (77.2%)
had received radiotherapy (whole brain or stereotactic),
and 5 patients (5.0%) had undergone surgery (Table 1).

www.TheOncologist.com

Furthermore, 21 patients (20.8%) reported taking corticosteroids, and 10 patients (9.9%) reported taking antiepileptics at baseline. Of the 101 patients with CNS disease at
baseline, 70 had baseline CNS scans that underwent retrospective central radiology review, and 3 of these were
found to have LMD (N + C, n = 2; L + C, n = 1; supplemental online Table 2). Additional patients with LMD may
have been enrolled, but information was not collected.

Efﬁcacy
In the CNS subgroup, independently adjudicated PFS and
OS were numerically improved with N + C compared with
L + C (Table 2). Mean PFS restricted at 24 months was
7.8 months (95% CI, 5.6–10.1) with N + C and 5.5 months
(95% CI, 3.8–7.2) with L + C, and median PFS was 5.6
months (95% CI, 3.7–7.1) and 4.3 months (95% CI, 2.8–5.6),
respectively (HR, 0.66; 95% CI, 0.41–1.05; Fig. 2). Mean OS
restricted at 48 months was 16.4 months (95% CI, 13.4–
19.5) with N + C and 15.4 months (95% CI, 12.1–18.8) with
L + C, and median OS was 13.9 months (95% CI, 8.9–17.5)
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Table 2. Efﬁcacy in patients with CNS metastases at baseline
Endpoint
Progression-free survivala
Restricted mean (95% CI),b mo

Time to intervention for CNS disease
12-month cumulative incidence (95% CI), %
p value (Gray’s test)
Progressive CNS diseasec
12-month cumulative incidence (95% CI), %
p value (Gray’s test)
CNS progression-free survivalc
Median (95% CI), mo
Hazard ratio (95% CI)
p value (Log-rank)
Objective response,a n (%)
Objective response rate (95% CI), %
p value (CMH test)
Duration of responsea,d
Median (95% CI), mo
Hazard ratio (95% CI)
p value (Log-rank)
Clinical beneﬁt,a no. (%)
Clinical beneﬁt rate (95% CI), %
p value (CMH test)

L + C (n = 50)

7.8 (5.6–10.1)

5.5 (3.8–7.2)

5.6 (3.7–7.1)

4.3 (2.8–5.6)
0.66 (0.41–1.05)
.074

16.4 (13.4–19.5)
13.9 (8.9–17.5)

15.4 (12.1–18.8)
12.4 (9.7–16.9)
0.90 (0.59–1.38)
.635

25.5 (14.4–38.1)

36.0 (22.9–49.3)
.430

26.2 (13.8–40.3)

41.6 (25.4–57.1)
.364

12.4 (5.6–17.9)

8.3 (4.3–NE)
0.62 (0.32–1.18)
.143

10/35 (28.6)
28.6 (14.6–46.3)

11/39 (28.2)
28.2 (15.0–44.9)
.972

8.3 (2.7–8.3)

5.3 (4.1–6.8)
0.47 (0.10–1.60)
.252

14/35 (40.0)
40.0 (23.9–57.9)

12/39 (30.8)
30.8 (17.0–47.6)
.410

a

Independently adjudicated.
b
At 24 months (progression-free survival) and 48 months (overall survival).
c
Scans read centrally.
d
Assessed in 10 and 11 patients in the N + C and L + C groups, respectively.
Abbreviations: CI, conﬁdence interval; CMH, Cochran Mantel-Haenszel; CNS, central nervous system; L + C, lapatinib plus capecitabine; N + C,
neratinib plus capecitabine; NE, not estimable.

and 12.4 months (95% CI, 9.7–16.9), respectively (HR, 0.90;
95% CI, 0.59–1.38; Fig. 2).
Cumulative incidence of interventions for CNS disease
at 6 months was 15.7% (95% CI, 7.3–27.0%) for N + C versus 24.0% (95% CI, 13.2–36.6%) for L + C and at 12 months
was 25.5% (95% CI, 14.4–38.1%) versus 36.0% (95% CI,
22.9–49.3%), respectively (Fig. 3A). Overall, 43 of 101
patients required interventions for CNS disease (including
radiotherapy, surgery, anti-cancer medications, and concomitant medications): 20 (39.2%) with N + C and 23 (46.0%)
with L + C; radiotherapy was the most commonly used posttreatment cancer-related intervention (N + C, n = 10; L + C,
n = 14; supplemental online Table 3). Cumulative incidence
of progressive CNS disease at 12 months was 26.2% (95% CI,
13.8–40.3%) for N + C versus 41.6% (95% CI, 25.4–57.1%) for

L + C (Fig. 3B). Median CNS-PFS was 12.4 months (95% CI,
5.6–17.9) for N + C versus 8.3 months (95% CI, 4.3 to not
estimable) for L + C (HR, 0.62; 95% CI, 0.32–1.18; Fig. 3C). A
summary of efﬁcacy outcomes in patients with baseline CNS
metastases is presented in Table 2.
Among the 32 patients with at least one target CNS
lesion identiﬁed at screening by the investigator, the conﬁrmed intracranial ORR per local assessment was 26.3%
with N + C and 15.4% with L + C. Intracranial response
rates and waterfall plots of best changes in tumor size from
baseline by treatment group are shown in Figure 4.
Among the three patients who had LMD at enrollment
(supplemental online Table 2), two patients treated with
N + C had disease progression after 5.6 and 9.8 months,
and OS times of 17.4 and 19.8 months, respectively. The
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Median (95% CI), mo
Hazard ratio (95% CI)
p value (Log-rank)
Overall survival
Restricted mean (95% CI),b mo
Median (95% CI), mo
Hazard ratio (95% CI)
p value (Log-rank)

N + C (n = 51)
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A

C

Figure 3. Time to intervention for CNS disease (A), progressive CNS disease (B), and CNS progression-free survival (C) in patients
with CNS metastases at baseline. For (B) and (C), scans read centrally.
Abbreviations: CI, conﬁdence interval; CNS, central nervous system; NE, not estimable.

other patient received L + C and had disease progression
after 4.3 months and OS of 6.5 months.

Safety
The median duration of study treatment was 5.7 months
(range, 0.4–28.6) for neratinib and 3.5 months (range, 0.5–
20.8) for lapatinib (supplemental online Table 4). Similar
proportions of patients in both groups required dose modiﬁcations. The general safety proﬁle observed was consistent
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with the safety proﬁle in the overall NALA safety population
[16], with diarrhea, nausea, vomiting, and palmar-plantar
erythrodysesthesia syndrome reported as the most common TEAEs of any grade (Table 3). Grade 3 diarrhea
occurred in 11 patients (22.0%) with N + C and 5 patients
(10.2%) with L + C, with no grade 4 diarrhea reported. No
patients discontinued N + C because of diarrhea, compared
with 2 patients (4.1%) receiving L + C. Common CNS
adverse events (grade 1–4) included headache (N + C,
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A

Figure 4. Best changes in intracranial tumor size from baseline for patients with target CNS lesions at screening per local assessment.
Hatched bar indicates patient has conﬁrmed response. Note: One patient in the lapatinib plus capecitabine group did not have a
follow-up assessment and is not included in Fig. 4B.
Abbreviations: CI, conﬁdence interval; CNS, central nervous system; L + C, lapatinib + capecitabine; N + C, neratinib plus capecitabine.

18.0% vs. L + C, 28.6%), dizziness (18.0% vs. 16.3%),
hemiparesis (4.0% vs. 4.1%), seizure (4.0% vs. 4.1%), and
gait disturbance (0% vs. 8.2%; supplemental online Table 5).
CNS-related TEAEs were slightly more common in the CNS
subgroup than the overall safety population [16]; for example, headache was reported in 23.2% of patients versus
13.5% in the overall safety population and dizziness in
17.2% versus 12.1%, respectively.

HRQoL
In the CNS subgroup, mean EORTC QLQ-C30 summary and
global health status scores and QLQ-BR23 systemic therapy
side effect scores over time were similar between treatment groups (supplemental online Fig. 1) and consistent
with the overall HRQoL population [16, 24].

DISCUSSION
Patients with asymptomatic or stable brain metastases
(treated or untreated) from HER2-positive MBC were eligible
to enroll in the phase III NALA trial and made up 16% of the
total population. All patients in this subgroup had received
two or more lines of systemic HER2-directed therapy, and
80% had undergone CNS-directed radiotherapy and/or surgery prior to study entry. Descriptive analyses of this patient
subgroup suggest that N + C is associated with improved
PFS compared with L + C as in the NALA intention-to-treat
population [16], despite having a poorer prognosis (mean OS

7–8 months shorter vs. intention-to-treat population [16]). In
addition, N + C was associated with improvements in all CNS
endpoints (time to intervention for CNS disease, time to progressive CNS disease, CNS-PFS, and intracranial ORR) when
compared with L + C. These CNS beneﬁts were apparent
despite the use of a lower dose of capecitabine with N + C
than L + C (1,500 vs. 2,000 mg/m2 per day). A unique feature of NALA was that patients with LMD were eligible to
enroll. Three patients with LMD were identiﬁed after independent radiology review, two of whom were treated with
N + C with good outcomes, supporting similar observations
from another recent study of N + C [14]. Neurological
adverse events were slightly more common in patients with
CNS metastases, as reported elsewhere [7], but no new
safety signals were observed.
These ﬁndings build on prior prospective studies demonstrating neratinib activity in both the prevention and treatment of CNS metastases from HER2-positive breast cancer
[12–15] and provide further support for the recommendation
to use neratinib-based therapy for brain metastases [25]. In
early-stage HER2-positive breast cancer, fewer patients developed CNS metastases as site of ﬁrst distant recurrence with
neratinib monotherapy compared with placebo in the
extended adjuvant setting [12, 13]. In the setting of locally
advanced or metastatic HER2-positive breast cancer, neratinib
plus chemotherapy (i.e., paclitaxel or capecitabine) reduced
the incidence of CNS-related events [15, 16] and delayed time
to CNS metastases [15]. Promising CNS ORR were also
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Table 3. Common treatment-emergent adverse events in patients with CNS metastases at baseline (occurring in ≥10
patients)
N + C (n = 50)
Grade 1–4
50 (100)
41 (82.0)
28 (56.0)
25 (50.0)
23 (46.0)
19 (38.0)
19 (38.0)

Grade 1–4
48 (98.0)
33 (67.3)
19 (38.8)
16 (32.7)
22 (44.9)
8 (16.3)
18 (36.7)

Grade 3/4
30 (61.2)
5 (10.2)
3 (6.1)
1 (2.0)
6 (12.2)
0 (0.0)
2 (4.1)

Decreased appetite
Weight decreased
Stomatitis
Aspartate aminotransferase increased
Dizziness
Headache
Hypokalemia
Paronychia

18 (36.0)
17 (34.0)
11 (22.0)
9 (18.0)
9 (18.0)
9 (18.0)
9 (18.0)
9 (18.0)

1 (2.0)
1 (2.0)
0 (0.0)
0 (0.0)
1 (2.0)
0 (0.0)
4 (8.0)
1 (2.0)

11 (22.4)
9 (18.4)
14 (28.6)
1 (2.0)
8 (16.3)
14 (28.6)
8 (16.3)
11 (22.4)

1 (2.0)
1 (2.0)
1 (2.0)
0 (0.0)
0 (0.0)
0 (0.0)
3 (6.1)
0 (0.0)

7 (14.0)
7 (14.0)
4 (8.0)
4 (8.0)
4 (8.0)
3 (6.0)

0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
1 (2.0)

8 (16.3)
9 (18.4)
7 (14.3)
17 (34.7)
7 (14.3)
9 (18.4)

1 (2.0)
1 (2.0)
1 (2.0)
1 (2.0)
0 (0.0)
3 (6.1)

Data presented as n (%).
Abbreviations: CNS, central nervous system; L + C, lapatinib plus capecitabine; N + C, neratinib plus capecitabine.

reported with N + C in patients with measurable, progressive
CNS metastases (lapatinib-naive patients, 49%; lapatinibpretreated patients, 33%) [14].
The recent approval of tucatinib based on the
HER2CLIMB study [26] has been a key milestone in conﬁrming the role of systemic therapy in HER2-positive
patients with brain metastases. Our analyses from NALA
provide further support for the efﬁcacy of TKIs, although
differences in the design and inclusion criteria of these two
studies should be noted. HER2CLIMB compared tucatinibtrastuzumab-capecitabine
with
placebo-trastuzumabcapecitabine in patients with HER2-positive metastatic
breast cancer previously treated with HER2-directed
therapy and was positive both for PFS and OS in the
intention-to-treat and brain metastases populations [26].
The presence of brain metastases was a stratiﬁcation factor,
and brain MRI at baseline was mandatory. Patients with
untreated, treated and stable, and treated and progressing
brain metastases were eligible, whereas patients with LMD
were excluded [27]. Additional inclusion criteria were speciﬁed regarding the size of untreated lesions (<2.0 cm or
requiring further approval) and restrictions for corticosteroid doses (dexamethasone ≤2 mg per day or equivalent)
[27]. In NALA, patients with treated or untreated asymptomatically stable brain metastases, including LMD, were
eligible but without restrictions on tumor size or
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corticosteroid doses (doses up to 8 mg per day were documented in some patients during the study). No CNS imaging
was required at enrollment, so patients with stable or progressing brain metastases may have been included. It is
likely NALA included a more heterogeneous population,
including some patients with more advanced CNS disease.
Within the context of current treatment guidelines,
ﬁrst-line treatment for patients with HER2-positive metastatic breast cancer remains unchanged regardless of CNS
involvement. Local CNS-directed therapy is typically recommended upon ﬁrst intracranial progression followed by
systemic therapy [25], the choice of which will likely depend
on the status of extracranial and intracranial disease
(i.e., treated stable, treated progressive, or untreated
asymptomatic). Although there are currently no clinical data
on which to base decisions about sequencing tucatinibbased and neratinib-based regimens beyond the secondline setting in patients with CNS progression, it is likely that
the choice will depend on multiple patient-speciﬁc factors
including prior treatments, feasibility of oral versus intravenous administration, preference for triplet versus doublet
therapy, as well as tolerance for capecitabine.
Effective drug delivery into the brain remains a signiﬁcant challenge in the treatment of CNS metastases. In theory, small-molecule TKIs, such as neratinib, may cross the
blood-brain barrier more effectively than macromolecular
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Adverse event
Any event
Diarrhea
Nausea
Vomiting
Palmar-plantar erythrodysesthesia syndrome
Constipation
Fatigue

Abdominal pain
Anemia
Pyrexia
Rash
Back pain
Asthenia

Grade 3/4
30 (60.0)
11 (22.0)
2 (4.0)
1 (2.0)
6 (12.0)
0 (0.0)
2 (4.0)

L + C (n = 49)
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CONCLUSION

These subgroup analyses support the beneﬁts of N + C in
patients with CNS metastases from HER2-positive MBC
compared with L + C as demonstrated in the intention-totreat population. Our ﬁndings support a role for neratinib
as a systemic treatment option in the management of
patients with HER2-positive brain metastases following
antibody-based HER2-directed therapies.
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HER2-directed monoclonal antibodies (trastuzumab, pertuzumab) and antibody-drug conjugates (trastuzumab
emtansine, trastuzumab deruxtecan). This is supported by
the TBCRC-022 study, which showed the presence of
neratinib in CNS surgical specimens, although distribution
within the samples was heterogeneous [28]. Variable drug
levels within brain metastases have also been observed
with other TKIs [29], suggesting that molecular size and
other factors (e.g., disruption of blood-brain barrier in the
presence of brain metastases, mechanisms regulating transport across the blood-brain barrier [30]) are likely to inﬂuence CNS penetration. It has been suggested that
irreversible TKIs, such as neratinib, may require less brain
penetration than reversible inhibitors in order to achieve
the same pharmacodynamic effect [31], but this has yet to
be formally investigated. Neratinib also inhibits the transporter ATP-binding cassette B1 (ABCB1; P-glycoprotein),
which is found in the blood-brain barrier [32] and may act
to reverse ABCB1-mediated chemotherapeutic resistance.
Further tissue-based and imaging studies are required to
improve understanding of CNS bioavailability, and to what
extent it determines therapeutic efﬁcacy [5, 28].
In the NALA CNS population, approximately half of the
patients had hormone receptor-positive (HR+) tumors, but
concomitant endocrine therapy was not permitted as it is
not considered standard of care [17]. The ExteNET and
SUMMIT trials showed that neratinib has appreciable efﬁcacy in patients with HR+/HER2-positive or HER2-mutated
breast cancer who are also receiving endocrine therapy [12,
33], an observation attributed to inhibition of bidirectional
cross-talk between HER2 and estrogen receptor (ER) signaling. Because estrogen can cross the blood-brain barrier
[34], it is possible that neratinib efﬁcacy in CNS metastases
may be further improved by adding endocrine therapy in
HR+ patients, although a possible confounding factor is
that the intrinsic molecular subtype of primary breast
tumors differs from matched brain metastases in up to 20%
of cases (predominantly through loss of hormone receptor
expression or gain of HER2 overexpression) [35, 36].
We acknowledge limitations of the present analyses.
Although patients with CNS metastases and LMD were eligible for inclusion in NALA, the study was not speciﬁcally
designed to evaluate these patients in detail. As such, the
present analyses rely on available data and on the assessments of local investigators and radiologists for some endpoints. The study protocol also did not require universal
CNS imaging at screening, and CNS disease stability was
based on clinical assessment and absence of CNS symptoms. As a result, disease progression due to a new lesion
in the brain could have been due to an undetected preexisting lesion at baseline. It is also possible that a few
patients with baseline CNS metastases or LMD may have
been missed. Prior radiotherapy was permitted if completed within 14 days before study treatment, but the exact
washout times for each patient were not available. Patients
with unstable or symptomatic brain metastases were not
eligible for NALA and our ﬁndings should not be extended
to these patients.
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